GlassScriptPhysician profile
Laura K Schroeder
NPI 1831193556
$12,237.84
in general payments reported to CMS, 2019-2025
43 companies · $2,273 in 2025
The $2,273 reported for 2025 was more than what 86% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,475 · 2020: $617 · 2021: $1,674 · 2022: $2,053 · 2023: $2,181 · 2024: $1,964 · 2025: $2,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,065 · Education: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,065.32 |
| Education | $352.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,777.86 | 2019-2025 | Dovato, Rukobia, Apretude |
| Gilead Sciences, INC. | $2,622.57 | 2019-2025 | Veklury, Yeztugo, Sunlenca |
| Merck Sharp & Dohme LLC | $1,117.91 | 2019-2025 | Dificid, Pifeltro, Delstrigo |
| Insmed, INC. | $778.37 | 2019-2025 | Arikayce, Brinsupri |
| Melinta Therapeutics, LLC | $711.05 | 2023-2025 | Rezzayo, Kimyrsa, Vabomere |
| Paratek Pharmaceuticals, INC. | $665.09 | 2021-2024 | Nuzyra |
| Abbvie INC. | $495.88 | 2020-2025 | Avycaz, Dalvance, Teflaro |
| Actelion Pharmaceuticals US, INC. | $393.32 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Astellas Pharma US INC | $385.93 | 2019-2025 | Cresemba, Ambisome |
| Shionogi INC | $243.97 | 2022-2025 | Fetroja |
| Janssen Products, LP | $214.74 | 2022 | |
| United Therapeutics Corporation | $193.83 | 2022-2025 | Tyvaso, Tyvaso, Remodulin |
| Astrazeneca Pharmaceuticals LP | $192.36 | 2023-2025 | Tezspire, Fasenra, Airsupra |
| Theratechnologies INC. | $191.11 | 2019-2021 | |
| Janssen Biotech, INC. | $158.10 | 2019-2023 | Remicade, Stelara, Simponi Aria |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $128.55 | 2025 | Ohtuvayre |
| La Jolla Pharmaceutical Company | $101.67 | 2025 | Zevtera |
| Takeda Pharmaceuticals U.S.A., INC. | $85.46 | 2022-2024 | Glassia |
| Mylan Specialty L.P. | $81.37 | 2022-2024 | Yupelri |
| Electromed, INC. | $64.24 | 2025 | Smartvest |
| Napo Pharmaceuticals INC | $64.12 | 2019-2025 | Mytesi |
| Ucb, INC. | $61.83 | 2024-2025 | Bimzelx |
| Baxter Healthcare | $50.86 | 2022-2023 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Viatris Specialty LLC | $45.25 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.85 | 2023-2024 | Cyltezo |
| Regeneron Healthcare Solutions, INC. | $39.11 | 2025 | Dupixent |
| Glaxosmithkline, LLC. | $32.31 | 2023 | Trelegy Ellipta, Arexvy, Nucala |
| Amgen INC. | $31.89 | 2022-2025 | Tezspire |
| Pharmacosmos Therapeutics INC. | $29.87 | 2022 | |
| Janssen Scientific Affairs, LLC | $28.23 | 2023 | Symtuza |
| Mayne Pharma Commercial LLC | $27.64 | 2019-2020 | |
| Genentech USA, INC. | $24.03 | 2024 | Xolair |
| Cmp Pharma, INC. | $21.89 | 2023 | Norliqva, Carospir, Tadliq |
| Jazz Pharmaceuticals INC. | $21.18 | 2021 | |
| Philips North America LLC | $15.19 | 2025 | Incourage Airway Clearance Therapy |
| Kowa Pharmaceuticals America, INC. | $14.92 | 2019 | |
| Pulmonx Corporation | $14.67 | 2022 | |
| Genzyme Corporation | $13.17 | 2023 | |
| Pfizer INC. | $12.78 | 2022 | |
| Nabriva Therapeutics, Plc | $12.28 | 2021 | |
| Advanced Respiratory, INC | $11.84 | 2021 | |
| Novo Nordisk INC | $11.67 | 2022 | |
| 3b Medical, INC. | $9.88 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Schroeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.